Article Text

Download PDFPDF
Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet
  1. P J Lee1,
  2. A Amos2,
  3. L Robertson1,
  4. B Fitzgerald3,
  5. R Hoskin4,
  6. M Lilburn1,
  7. E Weetch5,
  8. G Murphy2
  1. 1
    Charles Dent Metabolic Unit, National Hospital for Neurology & Neurosurgery, London, UK
  2. 2
    The Tizard Centre, University of Kent, Canterbury, UK
  3. 3
    Department of Learning Disabilities Psychiatry, Enfield PCT, Enfield, UK
  4. 4
    Learning Disabled Unit, NW Herts NHS Trust, St Albans, UK
  5. 5
    National Society for Phenylketonuria, London, UK
  1. Professor G Murphy, Tizard Centre, University of Kent, Canterbury CT2 7LZ, UK; g.h.murphy{at}


Background: Although early diagnosis and treatment in phenylketonuria (PKU) leads to excellent outcomes, a population of adults born before the introduction of newborn screening exists. They can have severe intellectual disabilities and behavioural problems, and are often dependent on full-time carers. Anecdotal evidence suggests that a diet that lowers blood phenylalanine concentration can have significant benefits upon behaviour.

Methods: A prospective double-blind randomised placebo-controlled crossover trial of phenylalanine-restricted diet was performed in a group of 34 adults (aged 21–61 years, median 49) with late diagnosed PKU with severe challenging behaviour.

Results: Only 17 completed the 60 week study: seven withdrew before the end of the baseline period; five withdrew during the first diet period; five withdrew during the second diet period (after moving into placebo phase). The mean (SD) blood phenylalanine was 1570 (222) μmol/l during baseline, 553(158) μmol/l during the active phase and 1444 (255) μmol/l during the placebo phase. In the 22 participants exposed to both active and placebo phases, no differences were demonstrated in behaviour assessed by the Aberrant Behavior Checklist and Vineland Adaptive Behavior Scales, behaviour diaries or on video analysis of direct observations. However, 76% of carers’ comments were scored as positive during the active phase, compared with 54% during the placebo phase (χ2 = 38.06, p<0.001).

Conclusions: There are significant challenges in studying people with intellectual disabilities and considerable difficulties in instituting phenylalanine-restricted diet in this population. However, if attempted, there are potential benefits to quality of life for the individuals with PKU and their carers.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • See Editorial Commentary, p 585

  • Funding: The study was funded by generous grants from the Wellcome Trust and SHS International.

  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by an NHS Multi-site Research Ethics Committee and by each of the local research and development offices where participants resided.

  • Patient consent: Obtained.

Linked Articles

  • Editorial commentary
    Francjan van Spronsen
  • Editorial commentary
    Christopher Kennard